Kesmalea is developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules
Kesmalea is developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules. This is achieved through SELFTAC®, a platform designed to combine the power of protein degradation with advantages such as oral bioavailability and central nervous system (CNS) penetration.